Evidence map›Paper›PMID 32209360›Full record

ArticleMetabolism: clinical and experimental2020

Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.

Jehnan Liu, Harrison T Muturi, Saja S Khuder, Raghd Abu Helal, Hilda E Ghadieh, Sadeesh K Ramakrishnan, Meenakshi K Kaw, Sumona Ghosh Lester, Ahmed Al-Khudhair, Philip B Conran and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolism: clinical and experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Frontiers in genetics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jehnan LiuCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Harrison T MuturiCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.
Saja S KhuderCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Raghd Abu HelalDepartment of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.
Hilda E GhadiehCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.
Sadeesh K RamakrishnanCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Meenakshi K KawCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Sumona Ghosh LesterCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Ahmed Al-KhudhairCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43614, USA.
Philip B ConranDepartment of Pathology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Khew-Voon ChinCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43614, USA.
Cara Gatto-WeisCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Pathology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Sonia M NajjarCenter for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA; Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA; Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, 45701, USA. Electronic address: najjar@ohio.edu.
University of Toledo · USOhio University · US

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Kevan C Herold, GERALD I SHULMAN · 1993 to 2026
$44.0M
SUBSTRATES AND INSULIN RECEPTOR ENDOCYTOSISR01DK054254 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI NAJJAR, SONIA M. · 2000 to 2021
$5.8M
CEACAM1: A link between metabolic and cardiovascular diseasesR01HL112248 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI NAJJAR, SONIA M. · 2012 to 2016
$1.9M
Insulin resistance in the pathogenesis of NASHR01DK083850 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI NAJJAR, SONIA M. · 2009 to 2010
$749k
NHLBI NIH HHS R01 HL112248NIDDK NIH HHS P30 DK045735NIDDK NIH HHS R01 DK054254NIDDK NIH HHS R01 DK083850
6 · The paper itself

Abstract

objectivePTEN haploinsufficiency plays an important role in prostate cancer development in men. However, monoallelic deletion of Pten gene failed to induce high prostate intraepithelial neoplasia (PIN) until Pten

methodsPten

resultsDeleting Ceacam1 in Pten

conclusionsCeacam1 deletion accelerated high-grade prostate intraepithelial neoplasia in Pten haploinsufficient mice while preserving insulin sensitivity. This demonstrated that the combined loss of Ceacam1 and Pten advanced prostate cancer by increasing lipogenesis and modifying the STAT3-dependent inflammatory microenvironment of prostate.

Indexed as

AnimalsCarcinoembryonic AntigenDisease ProgressionHaploinsufficiencyMaleMiceMice, Inbred C57BLMice, KnockoutMutationOncogene Protein v-aktPhosphatidylinositol 3-KinasesProstatic NeoplasmsPTEN PhosphohydrolaseSignal TransductionSTAT3 Transcription FactorCarcinoembryonic AntigenCeacam1 protein, mouseOncogene Protein v-aktPhosphatidylinositol 3-KinasesPTEN PhosphohydrolasePten protein, mouseStat3 protein, mouseSTAT3 Transcription FactorCEACAM1Fatty acid synthaseNeoplasiaNormoinsulinemiaPMLProstate intraepithelial neoplasiaPTEN tumor suppression

Identifiers

PMID32209360
PMCPMC7283002
OpenAlexW3012691586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.